In September, global pharmaceutical giant Johnson & Johnson (J&J) announced that results from its Phase III MARIPOSA trial—evaluating the Rybrevant + Lazertinib combination for non-small cell lung cancer (NSCLC)—were published in the New England Journal of Medicine (NEJM).

Overall survival (OS), defined as the time from treatment initiation to death, is the most direct measure of a cancer therapy’s life-prolonging potential. J&J reported that the median OS (mOS) for the Rybrevant–Lazertinib regimen is expected to exceed four years. Since the exact figure has not yet been released, it suggests that more than half of the patients in the treatment group remain alive—indicating a strong and durable survival benefit.

The regimen outperformed existing standards, exceeding the 37.6-month mOS of Tagrisso (osimertinib) and even the 47.5-month mOS recently reported for Tagrisso combined with chemotherapy. At a median follow-up of 37.8 months, the Rybrevant–Lazertinib arm significantly reduced the risk of death compared to Tagrisso alone.

This clinical success has translated into commercial growth. J&J reported Q3 2025 combined sales of $198 million for Rybrevant and Lazertinib, up 122.5 % from the same period last year. Revenue for the first nine months of 2025 reached $518 million, qualifying the therapy as a global blockbuster with 152.7 % year-on-year growth.

Analysts expect this trajectory to continue as Lazertinib’s subcutaneous (SC) formulation nears U.S. approval. The SC version, which cuts administration time from five hours (IV) to just 5–10 minutes, is projected to boost patient convenience and expand market uptake.

J&J CEO Joaquin Duato emphasized during the company’s Q3 earnings call that the Rybrevant–Lazertinib combination is “an asset projected to reach up to $5 billion in annual sales,” maintaining double-digit growth momentum.

Developed jointly with Yuhan Corporation, Rybrevant marks Korea’s 31st innovative drug. Following Yuhan’s 2018 out-licensing to J&J, the combination therapy received FDA approval in August 2024, followed by approvals in Europe (December 2024), the UK, Japan, and Canada (March 2025), and China (July 2025). Prescriptions began in Japan in May, underscoring rapid global rollout.

According to Nova One Advisor, the global NSCLC market—valued at $19.8 billion in 2023—is expected to reach $66.2 billion by 2033. NSCLC accounts for roughly 80–85 % of all lung cancers, reinforcing the Rybrevant–Lazertinib combination’s potential as a new global standard in targeted lung cancer therapy.